Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | Implementation of EEG as a biomarker in Alzheimer’s disease diagnosis and treatment monitoring

While electroencephalogram (EEG) is widely recognized for its utility in epilepsy and sleep disorders, its potential in Alzheimer’s disease (AD) is underestimated. Willem de Haan, PhD, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, discusses the implementation of EEG in diagnosis and monitoring treatment effects in AD. Despite its straightforward and cost-effective nature, EEG is often overshadowed by other imaging techniques. Dr de Haan identifies a lack of awareness and the challenges associated with technical data analysis as barriers to the widespread adoption of this technique in AD. This interview took place at the CTAD 2023 conference in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Willem de Haan reports the following disclosures: Our EEG lab performs EEG analysis in pharmaceutical trials by Cognition Therapeutics, Vivoryon, Immunobrain, Treeway and CervoMed (for which I do not receive personal compensation).